Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership
Details : Strides Pharma has entered into an exclusive partnership with Ennaid Therapeutics to focus on the development of an oral tablet, repurposed medication to treat mild, moderate, and asymptomatic cases of COVID‐19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 14, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Drospirenone,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ennaid Therapeutics Discovers Orally Deliverable Generic COVID-19 Drug
Details : Using its AI-based drug discovery platforms, Ennaid's scientific research team at the Universidad Catolica de Murcia (UCAM), in south-eastern Spain, identified the drug Drospirenone , as a solid therapeutic candidate showing significant antiviral activit...
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 30, 2020
Lead Product(s) : Drospirenone,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ENU200,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program
Details : Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a patent-pending, repurposed oral antiviral drug.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : ENU200,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ENU200,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ENU200 has demonstrated specific antiviral activity against two SARS-CoV-2 proteins, S glycoprotein and Mpro .
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2020
Lead Product(s) : ENU200,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable